Table 5 Features of non-anaemic patients at presentation who subsequently developed late fall in haematocrit below 30% 3 ā 6Ā weeks latera
Patient (gender, age) | Year of enrolment | Parasitaemia (Ī¼Lā1) | Enrolment HCT (%) | Antimalarial treatment | PCT (day) | Nadir HCT2 (%) [day] | HCT on day 42 (%) | AnRT1 (day) | AnRT2 (day) | AUC2 | FIH/1 000 parasites cpb | Total of mg/kg dose of AA | Total of mg/kg dose of AL | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Artesunate | Amodiaquine | Artemether | Lumefantrine | ||||||||||||
13 (F, 4.9y) | 2010 | 357 397 | 40 | AA | 2 | 27[21] | 30 | Ā | 14 | 24.68 | 0.0113 | 11.54 | 31.15 | NA | NA |
39 (M, 9y) | 2012 | 2 880 | 37 | AL | 1 | 24[21] | 32 | Ā | 7 | 6.57 | 0.3472 | NA | NA | 12.63 | 75.79 |
62 (M, 12y) | 2010 | 50 704 | 35 | AA | 2 | 27[42] | 27 | Ā | NA | NA | 0.0592 | 8.57 | 23.14 | NA | NA |
153 (F, 8y) | 2009 | 101 734 | 35 | AA | 1 | 28[28] | 32 | Ā | 7 | 2.64 | 0.0295 | 15 | 40.5 | NA | NA |
71 (M, 6y) | 2009 | 178 937 | 35 | AL | 1 | 28[21] | 34 | Ā | 7 | 2.64 | 0.0112 | NA | NA | 16.1 | 96.0 |
129 (M, 9y) | 2008 | 99 077 | 33 | AA | 1 | 29[21] | 45 | Ā | 7 | 1.52 | 0.0202 | 13.04 | 35.22 | NA | NA |
61 (M, 8.1y) | 2014 | 77 727 | 33 | AA | 1 | 20[28] | 37 | Ā | 7 | 10.13 | 0.0386 | 15.79 | 42.63 | NA | NA |
40 (F, 5.3y) | 2011 | 281 538 | 32 | AA | 2 | 29(35) | 34 | Ā | 7 | 1.52 | 0.0074 | 10.00 | 27.0 | NA | NA |
Mean | |||||||||||||||
Age (7.8y) | Ā | 82 078b | 35 | Ā | 1.38 | 27.6 | 33.88 | Ā | 8 | 7.1 | 0.066 | 12.32 | 33.27 | 14.36 | 85.9 |